Table 3 Multivariate Cox Proportional Hazards analysis of EGFR clusters with clinical parameters in NKI295 data set
From: EGFR associated expression profiles vary with breast tumor subtype
| Â | Relapse Free Survival | Overall Survival | ||
|---|---|---|---|---|
Variable | Hazard Ratio (95% CI) | p-value | Hazard Ratio (95% CI) | p-value |
Standard clinical parameters | ||||
Age, per decade | 0.59 (0.43–0.81) | 0.001 | 0.67 (0.45–0.99) | 0.04 |
ER status | 0.64 (0.42–0.98) | 0.04 | 0.45 (0.27–0.71) | 0.0009 |
Size | 1.38 (0.94–2.02) | 0.10 | 1.50 (0.94–2.41) | 0.09 |
Tumor grade 2 vs. 1 | 2.41 (1.31–4.43) | 0.005 | 4.30 (1.48–12.35) | 0.007 |
Tumor grade 3 vs. 1 | 2.58 (1.38–4.81) | 0.003 | 6.02 (2.09–17.35) | 0.0009 |
Nodes 1–3 vs. 0 | 0.85 (0.55–1.32) | 0.48 | 0.91 (0.53–1.56) | 0.72 |
Nodes >3 vs. 0 | 1.37 (0.83–2.26) | 0.22 | 1.56 (0.85–2.85) | 0.14 |
Standard clinical parameters and Cluster #1 | ||||
Age, per decade | 0.59 (0.43–0.82) | 0.002 | 0.67 (0.45–0.99) | 0.05 |
ER status | 0.67 (0.43–1.04) | 0.08 | 0.45 (0.27–0.75) | 0.002 |
Size | 1.35 (0.92–1.99) | 0.12 | 1.48 (0.92–2.39) | 0.11 |
Tumor grade 2 vs. 1 | 2.26 (1.23–4.18) | 0.009 | 4.13 (1.42–11.98) | 0.009 |
Tumor grade 3 vs. 1 | 2.21 (1.16–4.22) | 0.02 | 5.34 (1.81–17.74) | 0.002 |
Nodes 1–3 vs. 0 | 0.82 (0.56–1.27) | 0.38 | 0.86 (0.50–1.50) | 0.60 |
Nodes >3 vs. 0 | 1.23 (0.73–2.06) | 0.43 | 1.46 (0.79–2.71) | 0.23 |
Cluster #1 med vs. low | 1.53 (0.93–2.53) | 0.10 | 1.25 (0.65–2.39) | 0.50 |
Cluster #1 high vs. low | 1.70 (1.01–2.88) | 0.05 | 1.43 (0.76–2.69) | 0.27 |
Standard clinical parameters and Cluster #2 | ||||
Age, per decade | 0.60 (0.43–0.83) | 0.002 | 0.67 (0.452–0.99) | 0.04 |
ER status | 0.73 (0.46–1.16) | 0.18 | 0.54 (0.32–0.91) | 0.02 |
Size | 1.41 (0.96–2.07) | 0.08 | 1.52 (0.94–2.44) | 0.09 |
Tumor grade 2 vs. 1 | 1.94 (1.05–3.61) | 0.04 | 3.36 (1.15–9.83) | 0.03 |
Tumor grade 3 vs. 1 | 1.74 (0.90–3.37) | 0.10 | 3.54 (1.20–10.73) | 0.02 |
Nodes 1–3 vs. 0 | 0.80 (0.52–1.23) | 0.31 | 0.81 (0.47–1.39) | 0.44 |
Nodes >3 vs. 0 | 1.19 (0.71–1.98) | 0.51 | 1.36 (0.74–2.49) | 0.32 |
Cluster #2 med vs. low | 2.13 (1.22–3.71) | 0.008 | 2.10 (0.95–4.64) | 0.07 |
Cluster #2 high vs. low | 2.63 (1.44–4.79) | 0.002 | 3.46 (1.58–7.59) | 0.002 |
Standard clinical parameters and Cluster #3 | ||||
Age, per decade | 0.58 (0.42–0.81) | 0.001 | 0.67 (0.45–0.98) | 0.04 |
ER status | 0.68 (0.43–1.07) | 0.10 | 0.45 (0.27–0.76) | 0.003 |
Size | 1.39 (0.95–2.03) | 0.10 | 1.49 (0.93–2.41) | 0.10 |
Tumor grade 2 vs. 1 | 2.30 (1.24–4.24) | 0.008 | 4.13 (1.42–12.00) | 0.009 |
Tumor grade 3 vs. 1 | 2.29 (1.20–4.38) | 0.01 | 5.38 (1.83–15.80) | 0.002 |
Nodes 1–3 vs. 0 | 0.83 (0.54–1.29) | 0.41 | 0.86 (0.50–1.49) | 0.60 |
Nodes >3 vs. 0 | 1.30 (0.79–2.16) | 0.31 | 1.47 (0.80–2.70) | 0.22 |
Cluster #3 med vs. low | 1.32 (0.81–2.16) | 0.26 | 1.54 (0.80–2.95) | 0.20 |
Cluster #3 high vs. low | 1.41 (0.84–2.37) | 0.19 | 1.43 (0.73–2.78) | 0.29 |